Showing results (11-20 of 165) with videos related to
Sort By:
Pageof 17
Molecular and Cellular Endocrinology|February 8, 2017
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasmsJennifer M O'Sullivan, Claire N HarrisonExpert Opinion on Pharmacotherapy|April 1, 2026
Combination treatments for myelofibrosis in jak inhibitor-naive patients: evidence, rationale, and clinical directionLaura Li Gagnon, Claire N HarrisonHematology/Oncology Clinics of North America|October 17, 2003
Essential thrombocythemiaClaire N Harrison, Anthony R GreenBest Practice & Research. Clinical Haematology|June 20, 2006
Essential thrombocythaemiaClaire N Harrison, Anthony R GreenClinical Advances in Hematology & Oncology : H&O|May 10, 2018
Myelofibrosis: clinicopathologic features, prognosis, and managementJennifer M O'Sullivan, Claire N HarrisonBritish Journal of Haematology|March 14, 2020
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasmsDonal P McLornan, Claire N HarrisonFuture Oncology (London, England)|October 24, 2017
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasmsNatalia Curto-Garcia, Claire N HarrisonHematology. American Society of Hematology. Education Program|February 20, 2015
Management of MPN beyond JAK2Claire N Harrison, Natalia Curto GarciaBlood|June 7, 2024
How I treat patients with low-risk polycythemia vera who require cytoreductionMary Frances McMullin, Claire N HarrisonExpert Review of Hematology|March 9, 2018
Beyond JAK-2: potential targets for myeloproliferative neoplasm therapyPatrick M Harrington, Claire N HarrisonPageof 17